麦克林筹备上市：董事长杨勇组建近200人研发团队，打破高端试剂进口垄断

Group 1 - The core viewpoint of the article is that Shanghai McLean Biochemical Technology Co., Ltd. is preparing for an IPO on the ChiNext board, with the counseling period set from April 1, 2025, to June 30, 2025 [2] - McLean was established on December 10, 2013, with a registered capital of 33.769911 million RMB, and is primarily engaged in the manufacturing and supply of high-end research reagents [4] - The company has over 180,000 types of scientific reagent products and maintains a stock of 5 million bottles, which is continuously growing [5] Group 2 - The controlling shareholder, Yang Yong, holds 28.61% of the company and has led efforts to achieve import substitution since its inception [7] - McLean has built a research and development team of nearly 200 people, including over 10 PhDs and more than 50 master's degree holders, and has established standard research laboratories in Shanghai and Shandong [7] - The company has developed over 2,000 import substitution products in the high-end research reagent field, which has historically been dominated by foreign brands, with 90% of high-end reagents relying on imports [8]